KR101633742B1 - 아포 ａ에 활성인 티에노트리아졸로디아제핀 유도체 - Google Patents

아포 ａ에 활성인 티에노트리아졸로디아제핀 유도체 Download PDF

Info

Publication number
KR101633742B1
KR101633742B1 KR1020117012290A KR20117012290A KR101633742B1 KR 101633742 B1 KR101633742 B1 KR 101633742B1 KR 1020117012290 A KR1020117012290 A KR 1020117012290A KR 20117012290 A KR20117012290 A KR 20117012290A KR 101633742 B1 KR101633742 B1 KR 101633742B1
Authority
KR
South Korea
Prior art keywords
och
compound
formula
meta
hydrogen
Prior art date
Application number
KR1020117012290A
Other languages
English (en)
Korean (ko)
Other versions
KR20110091523A (ko
Inventor
헤르만 켐펜
다니엘 벨루스
바바라 스타에헬린
Original Assignee
써코메드 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 써코메드 엘엘씨 filed Critical 써코메드 엘엘씨
Publication of KR20110091523A publication Critical patent/KR20110091523A/ko
Application granted granted Critical
Publication of KR101633742B1 publication Critical patent/KR101633742B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020117012290A 2008-10-30 2009-10-29 아포 ａ에 활성인 티에노트리아졸로디아제핀 유도체 KR101633742B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167982.1 2008-10-30
EP08167982 2008-10-30

Publications (2)

Publication Number Publication Date
KR20110091523A KR20110091523A (ko) 2011-08-11
KR101633742B1 true KR101633742B1 (ko) 2016-06-27

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117012290A KR101633742B1 (ko) 2008-10-30 2009-10-29 아포 ａ에 활성인 티에노트리아졸로디아제핀 유도체

Country Status (11)

Country Link
US (1) US8569288B2 (pt-PT)
EP (1) EP2362876B1 (pt-PT)
JP (1) JP5490811B2 (pt-PT)
KR (1) KR101633742B1 (pt-PT)
CN (1) CN102292341B (pt-PT)
AU (1) AU2009309691B2 (pt-PT)
BR (1) BRPI0914406A2 (pt-PT)
CA (1) CA2741934C (pt-PT)
EA (1) EA018620B1 (pt-PT)
ES (1) ES2448567T3 (pt-PT)
WO (1) WO2010049466A1 (pt-PT)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
KR20210020889A (ko) 2018-06-13 2021-02-24 디블라이 아게 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176927B1 (de) 1984-10-01 1993-09-08 Boehringer Ingelheim Kg Diazepine enthaltende pharmazeutische Zusammensetzungen mit Plättchen aktivierender Faktor (PAF)-antagonistischer Wirkung
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
ATE86256T1 (de) * 1987-05-28 1993-03-15 Yoshitomi Pharmaceutical Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
WO1997009048A1 (en) * 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176927B1 (de) 1984-10-01 1993-09-08 Boehringer Ingelheim Kg Diazepine enthaltende pharmazeutische Zusammensetzungen mit Plättchen aktivierender Faktor (PAF)-antagonistischer Wirkung
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Also Published As

Publication number Publication date
EA201100698A1 (ru) 2011-12-30
BRPI0914406A2 (pt) 2015-10-20
EP2362876A1 (en) 2011-09-07
WO2010049466A1 (en) 2010-05-06
CN102292341B (zh) 2014-09-10
AU2009309691B2 (en) 2015-04-02
JP5490811B2 (ja) 2014-05-14
CA2741934C (en) 2016-09-13
KR20110091523A (ko) 2011-08-11
AU2009309691A1 (en) 2010-05-06
US20110230460A1 (en) 2011-09-22
CA2741934A1 (en) 2010-05-06
EP2362876B1 (en) 2013-12-11
CN102292341A (zh) 2011-12-21
JP2012506896A (ja) 2012-03-22
US8569288B2 (en) 2013-10-29
ES2448567T3 (es) 2014-03-14
EA018620B1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
KR101633742B1 (ko) 아포 ａ에 활성인 티에노트리아졸로디아제핀 유도체
AU702324B2 (en) Cyclic GMP-specific phosphodiesterase inhibitors
US8158792B2 (en) Spiropiperidines for use as tryptase inhibitors
TWI531573B (zh) 新穎反轉模擬物之化合物及其用途
CZ303707B6 (cs) Pouzití karbazolového derivátu, karbazolový derivát a farmaceutická kompozice, obsahující karbazolový derivát
JP2002532501A (ja) キノリン誘導体
JP2006501186A (ja) Ｍｃｈ１ｒアンタゴニスト
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
EA004373B1 (ru) 1-АМИНОТРИАЗОЛО[4,3-a]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ IV
JP2005525392A (ja) 減少された鎮静及び失調効果を有する抗不安薬剤
JP2010536736A (ja) ３位において二置換されているインドール−２−オン誘導体、これらの調製およびこれらの治療上の使用
TW200808779A (en) Novel compound
BG64989B1 (bg) Заместено триазолопиридазиново производно фармацевтични състави, получени от него
JP2005501858A (ja) オキシトシン作動薬としてのジアザシクロアルカン
KR20220042379A (ko) 키티나제 억제제로서 유용한 치환된 아미노 트리아졸
KR19990022940A (ko) 삼환성 벤즈아제핀 화합물
JP2006517530A (ja) オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
JP2013515725A (ja) ［４［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−（１ｈ−ピロロ−ピリジン−イル）−メタノン類及びその合成
KR20150074131A (ko) 1h-인돌-3-카복스아미드 유도체, 및 p2y12 길항제로서의 그의 용도
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
SK14992000A3 (sk) Spôsob inhibície mrpi
AU2006326247A1 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
KR20220015426A (ko) 캡시드 조립 조절제로서의 융합 복소환 유도체
TW201136938A (en) Spiropiperidine benzylamines as beta-tryptase inhibitors
KR101812128B1 (ko) 단백질 키나아제 저해제인 신규 5-아미노-3-(이속사졸-3-일)-1h-피라졸-4-카보아마이드 유도체들의 제조방법 및 약학적 활용

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant